Rocket Lab Corporation (NASDAQ: RKLB), initiation of coverage, Nov 10, 2026

Rocket Lab’s $55 price needs about 15% growth forever; we value it near $16

Rocket Lab is a fast-growing launch and satellite maker that still burns cash, and its big Neutron rocket is not yet flying. The market pays 44.0 times sales, while our weighted value is $13.83 a share.

Our rating
Sell
12-month target
$15.85
Price, Nov 10, 2026
$54.97
Expected return, with dividend
−71%

By Penmark Team

RKLBSellTarget $15.85−71% expectedFull report

What Rocket Lab is now

A rocket company that earns two-thirds of its sales from building satellites

Rocket Lab flies Electron, a small rocket, and builds satellites, solar panels and optics, mostly for governments. In 2025 Space Systems brought in $402.8m, 67% of revenue, and launches $199.0m.

Sales grew 9.7 times in four years, but every year burned cash. Of each 2025 dollar, 34 cents was gross profit and free cash flow was −53 cents. Neutron, a bigger reusable rocket, has not flown yet.

Satellites, not rockets, bring in most sales
Share of 2025 revenue67%33%
Space Systems (satellites and parts)Launch Services

Source: company filings.

Revenue per year
$211m2022$245m2023$436m2024$602m2025$982m2026
ReportedOur estimate

2026 is our estimate. Source: company filings, Penmark Research estimates.

How Rocket Lab makes money (page 8)

What you are really buying

Cash covers $7 of the $55 price, and about $28 has no explanation

Cash and investments of $4.70bn are worth $6.71 a share. Our base value, with the business and the Iridium deal, is $12.80, and the market pays 44.0 times sales against 3.9 times for peers.

Giving the market its view on all four debates adds $14.07, to $26.87, still half the price. The other $28.10 needs 14.6% growth forever. No single input closes the gap.

What the $54.97 price is made of, per share
$6.71Cash andinvestments+$6.09Business andIridium, our view+$14.07Market view onfour debates+$28.10Not explainedby any debate$54.97Today’sprice

Each debate is priced alone at the market view, with other inputs at base. Source: Penmark Research estimates.

The four debates (page 7)

Where we disagree: what the price implies

The price needs about 15% growth forever, which no scenario of ours gets near

We discount Rocket Lab’s cash flows at 14.65%, based on its own beta of 2.31. At a sector beta of 0.95 our value would be $18.75, a gain of $5.95.

To reach $54.97 the model needs 14.6% growth in perpetuity, or a 4.5% cost of equity, below the 4.9% risk-free rate. Even valuing Iridium at the 16.2 times deal multiple adds just $2.50.

Long-run growth: what the price needs against ours
What the price needs14.6%Our long-run growth3.0%

Long-run growth is the terminal growth rate in the discounted cash flow model. Source: Penmark Research estimates.

What the price implies (page 17)

Where we disagree: Neutron timing

Neutron has no flight date, and even 50 launches a year is worth only $17

Neutron’s first flight has been reset four times and is now no earlier than 2027. When it slipped in October, the shares fell 20.8% in three sessions.

We model one flight in 2027 and 18 a year by 2034, at $60m each. The market-implied path of 50 a year adds $3.83, taking value to $16.63, far below the $54.97 price.

Neutron launches a year in our base case
12027320285202982030

Source: Penmark Research estimates.

Neutron’s timeline (page 15)

Where we disagree: Space Systems growth

Satellite sales can grow 30% next year, but the price needs 37 points more

Space Systems brought in $214.8m in the third quarter, 80% of revenue, with a $1.71bn backlog behind it. We expect 30% growth in 2027, fading to 20% by 2030.

Our 2027 revenue of $1,324.6m is just 0.4% below analysts. The price instead needs 37.3 points more growth every year to 2040, and even the bull path adds only $1.78.

Space Systems revenue per year
$402.8m2025$743.0m2026$965.9m2027$1,207.3m2028$1,472.9m2029
ReportedOur estimate

2026 onward are our estimates. Source: company filings, Penmark Research estimates.

Space Systems growth (page 16)

The odds

Even the good case leaves the shares 48% below today’s price

Our middle case, 50% likely, has Neutron flying in 2027 and is worth $14.67 in 12 months. The good case, with 50 launches a year at $70m, reaches $28.73.

The bad case, 30% likely, has Neutron slipping to 2028 and is worth $9.23. Weighted together, the cases give our $15.85 target, a 71.2% fall from $54.97.

  • Good, 20%Neutron flies 50 times a year at $70m, satellite sales grow 45% fading to 6% and Iridium is worth 16.2 times: $28.73.
  • Middle, 50%Neutron flies in 2027 and reaches 18 a year at $60m, satellite sales grow 30% fading to 4%: $14.67.
  • Bad, 30%Neutron slips to 2028 and reaches 8 a year at $50m, satellite sales grow 18%, Iridium at 10.0 times: $9.23.
Where the price could be in 12 months
−$45.74 downToday $54.97$9.23Bad case$14.67Middle case$28.73Good caseOur target $15.85

Circle size shows how likely we think each case is. The target weights all three and adds 12 months of expected return. Source: Penmark Research.

All three cases (page 21)

What would change our mind

Only a fast Neutron ramp could move us, and alone it would not be enough

First comes the Stage 1 tank test in early 2027, then the first flight later that year. A fast ramp toward 50 launches a year would make us revisit the target.

The rating moves to Hold only if the price falls below $17.62 or our target rises above $49.47. No event on the calendar closes that gap on its own.

What bulls get right. Demand is real. Backlog is $3.57bn, up 52% in a quarter, with 16 Neutron missions booked, and revenue has not fallen below guidance in eight quarters.
Dates to watch
  1. We expect $280m of revenue, against analysts’ $266.4m, and 2027 launch growth above 20%.

  2. Stage 1 tank qualification. A further slip would cost $0.27 a share.

  3. We model one revenue flight. Two extra flights a year would be worth $0.30 a share.

  4. About 44m new shares. We assume a 90% chance of closing at 12.5 times profit.

  5. A lower rate on the EMSS renewal would put Iridium at 10.0 times and cost $1.66 a share.

Catalysts and risks (page 22)

Inside the full report

What each page covers after the summary on pages 1 and 2. Each opens the full report at that page.

See all 24 pages
  1. 3Margins turn positive in FY28E, and our FY27E EPS is 35% above a consensus set before the print
  2. 4Four dated events test the thesis; RKLB trades at 11x the peer sales multiple
  3. 5RKLB trades with the space sector, not its own numbers: the sector ETF explains 66% of weekly moves
  4. 6Over 12 months sales growth added $30.49 a share, but dilution and a lower multiple took $27.15
  5. 7Four debates are worth $14.07 a share at the market view; $28.10 of the $42.17 gap is left unexplained
  6. 8A rocket company that earns 80% of its revenue from satellites is valued at $38.5bn
  7. 9Space Systems earns 67% of revenue and Launch 33%; every dollar of FY25A gross profit was spent twice over on research and overhead
  8. 10Gross profit of $424m in FY27E still trails operating costs of $591m; Neutron closes the gap by FY30E
  9. 11Launch is a $12.4bn market and Rocket Lab flew 5.5% of the world’s 329 orbital attempts in 2025
  10. 12Shareholders funded $3.9bn of equity in nine months; share count is up 3.0x since FY21
  11. 13RKLB trades with the space-sector tape and the Neutron date, not with quarterly results
  12. 14The space ETF explains 66% of price variance; Neutron drew 30 of 112 analyst questions and management hedged on timing
  13. 15Neutron’s date is still unknown, and even a ramp 2.8x our base case is worth only $16.63 a share
  14. 16Space Systems is 73% of FY27E revenue; a 4-point drift in long-run margin costs more than any growth surprise
  15. 17At $54.97 the market pays 4.0x our probability-weighted $13.83; even the 12-month bull target of $28.73 is 47.7% below it
  16. 18Gross margin rose from −3.0% to 34.4% in four years, but every year burned cash and stock pay ran at 12% of FY25A revenue
  17. 19Q4 FY26E revenue of $280m sits at the guide midpoint; FY27E of $1,324.6m is 0.4% below consensus
  18. 20A DCF gives $11.11 and an Iridium-inclusive base of $12.80; the EV/sales cross-check gives $16.88, 31.9% higher
  19. 21The 12-month target of $15.85 is a −71.2% price return from $54.97, well below the −10% Sell threshold
  20. 22Five dated events test the thesis; the largest single risk to our Sell is the Neutron 50-a-year path, at +$3.83 a share
  21. 23Insiders sold $117m in four months with no purchases, and 18 of 22 analysts rate the stock Buy
  22. 24Net income turns positive in FY28E at $81m and reaches $472m in FY30E; EPS passes $0.67
  23. 25Revenue has risen for six straight quarters to $267.8m; gross margin has eased to 33.6% from 38.2% in Q1 FY26
  24. 26Reference: Q3 FY26 adjusted EBITDA of −$18.0m is −$79.7m of reported net income

Penmark Research. This summary draws on our initiation report on Rocket Lab Corporation, published Nov 10, 2026. It is not investment advice. Analyst certification, rating definitions and important disclosures are in the full report.

Sign in to Penmark